SeqOne Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SeqOne Genomics has established itself as a key enabler of precision medicine by offering a comprehensive, cloud-based bioinformatics platform that transforms complex genomic data into clinically actionable insights. Its core value proposition lies in combining automation, AI-driven variant prioritization (DiagAI Score), and robust security with a flexible, pay-per-analysis business model, serving over 160 labs across 30+ countries. The company is strategically positioned at the intersection of the growing demand for genomic testing in oncology, rare diseases, and infectious diseases, and the need for labs to manage increasing data complexity efficiently and cost-effectively.

OncologyRare DiseasesInfectious Diseases

Technology Platform

AI-powered, cloud-based genomic analysis platform (CE-IVD Class C) for NGS data. Features include DiagAI Score for variant prioritization, SeqOne Flow for workflow automation, and support for germline, somatic, and infectious disease analysis across panels, exomes, and genomes.

Opportunities

The global expansion of precision medicine and routine clinical NGS testing creates a massive, growing demand for automated, regulatory-compliant bioinformatics.

SeqOne can capitalize by expanding into new geographic markets (e.g., US, Asia) and by continuously adding support for new biomarkers and sequencing applications (e.g., long-read, epigenetics).

Risk Factors

Intense competition from both large sequencing companies with integrated platforms and other bioinformatics startups threatens market share.

The complexity and cost of maintaining IVDR Class C and other global regulatory certifications pose an ongoing operational and financial burden.

Customer acquisition can be slow in the conservative healthcare sector, requiring proven ROI and seamless integration.

Competitive Landscape

SeqOne competes in the clinical bioinformatics software market against integrated offerings from sequencing giants (Illumina, Thermo Fisher), standalone software providers (Sophia Genetics, Fabric Genomics, Pierian), and open-source/in-house solutions. Its key differentiators are its specific IVDR Class C certification as a standalone device, its patented security model, and its flexible, AI-driven platform that is sequencer-agnostic.

More companies in Diagnostics & Precision Medicine →More companies in France →